BeBetter Med Inc. is a biopharmaceutical company founded in 2012 in China by veteran U.S.-trained scientists. The company is publicly listed on the STAR Market of the Shanghai Stock Exchange. The company’s core product, Ifupinostat (BEBT-908)—the world’s first HDAC/PI3Kα dual-target inhibitor—was approved by China’s National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). In addition, the company is advancing two programs in Phase III and five programs in Phase I, underscoring a robust and diversified clinical pipeline.

BeBetter Pharma Inc.—the U.S. subsidiary based in Waltham, MA—leverages the company’s GDOC and POC platforms to accelerate next-generation siRNA therapeutics, drive U.S. and global clinical development, and support partnering and out-licensing initiatives for complex, high-burden diseases.